These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32639855)

  • 1. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
    Kunchok A; Lechner-Scott J; Granella F; Trojano M; Alroughani R; Sola P; Ferraro D; Lugaresi A; Onofrj M; Ozakbas S; Izquierdo G; Grammond P; Luis Sanchez-Menoyo J; Van Wijmeersch B; Boz C; Pucci E; McCombe P; Grand'Maison F; Spitaleri D; Vucic S; Hupperts R; Jokubaitis V; Sormani MP; Butzkueven H; Kalincik T;
    Mult Scler; 2021 Apr; 27(5):695-705. PubMed ID: 32639855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
    Ruggieri S; Prosperini L; Al-Araji S; Annovazzi PO; Bisecco A; Ciccarelli O; De Stefano N; Filippi M; Fleischer V; Evangelou N; Enzinger C; Gallo A; Garjani A; Groppa S; Haggiag S; Khalil M; Lucchini M; Mirabella M; Montalban X; Pozzilli C; Preziosa P; Río J; Rocca MA; Rovira A; Stromillo ML; Zaffaroni M; Tortorella C; Gasperini C;
    J Neurol Neurosurg Psychiatry; 2024 Jan; 95(2):142-150. PubMed ID: 37775266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a.
    Sormani MP; Freedman MS; Aldridge J; Marhardt K; Kappos L; De Stefano N
    Mult Scler Relat Disord; 2021 Apr; 49():102790. PubMed ID: 33571946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing response to interferon-β in a multicenter dataset of patients with MS.
    Sormani MP; Gasperini C; Romeo M; Rio J; Calabrese M; Cocco E; Enzingher C; Fazekas F; Filippi M; Gallo A; Kappos L; Marrosu MG; Martinelli V; Prosperini L; Rocca MA; Rovira A; Sprenger T; Stromillo ML; Tedeschi G; Tintorè M; Tortorella C; Trojano M; Montalban X; Pozzilli C; Comi G; De Stefano N;
    Neurology; 2016 Jul; 87(2):134-40. PubMed ID: 27306626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.
    Río J; Rovira À; Tintoré M; Otero-Romero S; Comabella M; Vidal-Jordana Á; Galán I; Castilló J; Arrambide G; Nos C; Tur C; Pujal B; Auger C; Sastre-Garriga J; Montalban X
    Mult Scler; 2018 Mar; 24(3):322-330. PubMed ID: 28287331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinal cord MRI activity in multiple sclerosis: Predictive value for relapses and impact on treatment decisions.
    Lorefice L; Piras C; Sechi V; Barracciu MA; Cocco E; Fenu G
    J Neurol Sci; 2024 Jul; 462():123057. PubMed ID: 38820738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
    Abdel-Mannan OA; Manchoon C; Rossor T; Southin JC; Tur C; Brownlee W; Byrne S; Chitre M; Coles A; Forsyth R; Kneen R; Mankad K; Ram D; West S; Wright S; Wassmer E; Lim M; Ciccarelli O; Hemingway C; Hacohen Y;
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34021056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
    Prosperini L; Mancinelli C; Haggiag S; Cordioli C; De Giglio L; De Rossi N; Galgani S; Rasia S; Ruggieri S; Tortorella C; Pozzilli C; Gasperini C
    J Neurol Neurosurg Psychiatry; 2020 Mar; 91(3):271-277. PubMed ID: 31974130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
    Daruwalla C; Shaygannejad V; Ozakbas S; Havrdova EK; Horakova D; Alroughani R; Boz C; Patti F; Onofrj M; Lugaresi A; Eichau S; Girard M; Prat A; Duquette P; Yamout B; Khoury SJ; Sajedi SA; Turkoglu R; Altintas A; Skibina O; Buzzard K; Grammond P; Karabudak R; van der Walt A; Butzkueven H; Maimone D; Lechner-Scott J; Soysal A; John N; Prevost J; Spitaleri D; Ramo-Tello C; Gerlach O; Iuliano G; Foschi M; Ampapa R; van Pesch V; Barnett M; Shalaby N; D'hooghe M; Kuhle J; Sa MJ; Fabis-Pedrini M; Kermode A; Mrabet S; Gouider R; Hodgkinson S; Laureys G; Van Hijfte L; Macdonell R; Oreja-Guevara C; Cristiano E; McCombe P; Sanchez-Menoyo JL; Singhal B; Blanco Y; Hughes S; Garber J; Solaro C; McGuigan C; Taylor B; de Gans K; Habek M; Al-Asmi A; Mihaela S; Castillo Triviño T; Al-Harbi T; Rojas JI; Gray O; Khurana D; Van Wijmeersch B; Grigoriadis N; Inshasi J; Oh J; Aguera-Morales E; Fragoso Y; Moore F; Shaw C; Baghbanian SM; Shuey N; Willekens B; Hardy TA; Decoo D; Sempere AP; Field D; Wynford-Thomas R; Cunniffe NG; Roos I; Malpas CB; Coles AJ; Kalincik T; Brown JWL
    Mult Scler; 2023 Jun; 29(7):875-883. PubMed ID: 36851894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.
    Kappos L; Moeri D; Radue EW; Schoetzau A; Schweikert K; Barkhof F; Miller D; Guttmann CR; Weiner HL; Gasperini C; Filippi M
    Lancet; 1999 Mar; 353(9157):964-9. PubMed ID: 10459905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
    Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
    Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis-A Prospective Cohort Study.
    Agrawal A; Srivastava MVP; Bhatia R; Goyal V; Singh MB; Vishnu VY; Prabhakar A
    Brain Sci; 2023 Aug; 13(9):. PubMed ID: 37759850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis.
    Lees S; Dicker M; Ku JE; Chaganti V; Mew-Sum M; Wang N; Smith A; Oldmeadow C; Goon WL; Bevan M; Lang D; Hinwood M
    BMJ Open; 2021 Nov; 11(11):e051509. PubMed ID: 34728450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
    Arnold DL; You X; Castrillo-Viguera C
    J Neurol; 2017 Aug; 264(8):1728-1734. PubMed ID: 28685353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.